Search Results - "MIDDLETON, M. R"

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours by Dean, E, Middleton, M R, Pwint, T, Swaisland, H, Carmichael, J, Goodege-Kunwar, P, Ranson, M

“…Background: Olaparib (AZD2281) is a potent oral poly(ADP-ribose) polymerase inhibitor with anti-tumour activity and acceptable toxicity as monotherapy in…”
Get full text

Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies by Moreno, V., Calvo, E., Middleton, M. R., Barlesi, F., Gaudy-Marqueste, C., Italiano, A., Romano, E., Marabelle, A., Chartash, E., Dobrenkov, K., Zhou, H., Connors, E. C., Zhang, Y., Wermke, M.

“…Background We evaluated MK-4621, an oligonucleotide that binds and activates retinoic acid–inducible gene I (RIG-I), as monotherapy (NCT03065023) and in…”
Get full text

The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population by ILLING, R. O, KENNEDY, J. E, WU, F, TER HAAR, G. R, PROTHEROE, A. S, FRIEND, P. J, GLEESON, F. V, CRANSTON, D. W, PHILLIPS, R. R, MIDDLETON, M. R

“…High-intensity focused ultrasound (HIFU) provides a potential noninvasive alternative to conventional therapies. We report our preliminary experience from…”
Get full text

An Adaptive Study to Determine the Optimal Dose of the Tablet Formulation of the PARP Inhibitor Olaparib by Mateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E., Middleton, M. R., Friedlander, M., Gourley, C., Plummer, R., Rustin, G., Sessa, C., Leunen, K., Ledermann, J., Swaisland, H., Fielding, A., Bannister, W., Nicum, S., Molife, L. R.

“…Background Olaparib is poorly soluble, requiring advanced drug delivery technologies for adequate bioavailability. Sixteen capsules/day are required for the…”
Get full text

A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours by Khan, O A, Gore, M, Lorigan, P, Stone, J, Greystoke, A, Burke, W, Carmichael, J, Watson, A J, McGown, G, Thorncroft, M, Margison, G P, Califano, R, Larkin, J, Wellman, S, Middleton, M R

“…Background: Poly adenosine diphosphate (ADP)-ribose polymerase (PARP) is essential in cellular processing of DNA damage via the base excision repair pathway…”
Get full text

DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma by Gupta, A., Love, S., Schuh, A., Shanyinde, M., Larkin, J.M., Plummer, R., Nathan, P.D., Danson, S., Ottensmeier, C.H., Lorigan, P., Collins, L., Wise, A., Asher, R., Lisle, R., Middleton, M.R.

“…Treatment options for wild-type BRAF melanoma patients remain limited. Selumetinib, a MEK 1/2 inhibitor, suppresses pERK levels independent of BRAF and NRAS…”
Get full text

Circulating melanoma cells and survival in metastatic melanoma by RAO, C, BUI, T, CONNELLY, M, DOYLE, G, KARYDIS, I, MIDDLETON, M. R, CLACK, G, MALONE, M, COUMANS, F. A. W, TERSTAPPEN, L. W. M. M

“…A validated assay for the enumeration of circulating melanoma cells (CMCs) may facilitate the development of more effective therapies for metastatic melanoma…”
Get full text

Toxic epidermal necrolysis in a patient receiving vemurafenib for treatment of metastatic malignant melanoma by Sinha, R., Lecamwasam, K., Purshouse, K., Reed, J., Middleton, M.R., Fearfield, L.

Get full text

High-intensity focused ultrasound for the treatment of liver tumours by Kennedy, J.E., Wu, F., ter Haar, G.R., Gleeson, F.V., Phillips, R.R., Middleton, M.R., Cranston, D.

“…High-intensity focused ultrasound (HIFU) has been investigated as a tool for the treatment of cancer for many decades, but is only now beginning to emerge as a…”
Get full text

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma by MIDDLETON, M. R, GROB, J. J, DRENO, B, HENZ, M, SCHADENDORF, D, KAPP, A, WEISS, J, FRAASS, U, STATKEVICH, P, MULLER, M, THATCHER, N, AARONSON, N, FIERLBECK, G, TILGEN, W, SEITER, S, GORE, M, AAMDAL, S, CEBON, J, COATES, A

“…To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall survival, progression-free survival…”
Get full text

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors by Macaulay, V.M., Middleton, M.R., Protheroe, A.S., Tolcher, A., Dieras, V., Sessa, C., Bahleda, R., Blay, J.-Y., LoRusso, P., Mery-Mignard, D., Soria, J.-C.

“…Type 1 insulin-like growth factor receptor (IGF-1R) mediates resistance to chemotherapy and targeted agents. This study assessed the safety, pharmacokinetics…”
Get full text

Societal preference values for advanced melanoma health states in the United Kingdom and Australia by Beusterien, K M, Szabo, S M, Kotapati, S, Mukherjee, J, Hoos, A, Hersey, P, Middleton, M R, Levy, A R

“…Background: No studies measure preference-based utilities in advanced melanoma that capture both intended clinical response and unintended toxicities…”
Get full text

Adjuvant Interferon in High-Risk Melanoma: The AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research Randomized Study of Adjuvant Low-Dose Extended-Duration Interferon Alfa-2a in High-Risk Resected Malignant Melanoma by HANCOCK, B. W, WHEATLEY, K, BURROWS, L, GORE, M, HARRIS, S, IVES, N, HARRISON, G, HORSMAN, J. M, MIDDLETON, M. R, THATCHER, N, LORIGAN, P. C, MARSDEN, J. R

“…To evaluate low-dose extended duration interferon alfa-2a as adjuvant therapy in patients with thick (> or = 4 mm) primary cutaneous melanoma and/or…”
Get full text

Translational study identifies XPF and MUS81 as predictive biomarkers for oxaliplatin-based peri-operative chemotherapy in patients with esophageal adenocarcinoma by MacGregor, T. P., Carter, R., Gillies, R. S., Findlay, J. M., Kartsonaki, C., Castro-Giner, F., Sahgal, N., Wang, L. M., Chetty, R., Maynard, N. D., Cazier, J. B., Buffa, F., McHugh, P. J., Tomlinson, I., Middleton, M. R., Sharma, R. A.

“…Oxaliplatin-based chemotherapy is used to treat patients with esophageal adenocarcinoma (EAC), but no biomarkers are currently available for patient selection…”
Get full text

Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma by Gillies, R. S., Middleton, M. R., Han, C., Marshall, R. E. K., Maynard, N. D., Bradley, K. M., Gleeson, F. V.

“…Background: Positron emission tomography combined with computed tomography (PET–CT) is increasingly being used in the staging of oesophageal cancer. Some…”
Get full text

Beyond the theory: From holobiont concept to microbiome engineering by Biggs, Eva, Taylor, Michael W., Middleton, Danielle M. R. L.

“…Holobiont research has increasingly moved from descriptive studies to sophisticated field‐ and laboratory‐based manipulations; however, the extent to which…”
Get full text

Multiple sclerosis health-related quality of life utility values from the UK MS register by Heather, A, Goodwin, E, Green, C, Morrish, N, Ukoumunne, OC, Middleton, RM, Hawton, A

“…Background New interventions for multiple sclerosis (MS) commonly require a demonstration of cost-effectiveness using health-related quality of life (HRQoL)…”
Get full text

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial by Cummings, J, Zweifel, M, Smith, N, Ross, P, Peters, J, Rustin, G, Price, P, Middleton, M R, Ward, T, Dive, C

“…Background: OXi4503 is a tubulin-binding vascular disrupting agent that has recently completed a Cancer Research UK-sponsored phase I trial. Preclinical…”
Get full text

16S rRNA gene-based meta-analysis of the reptile gut microbiota reveals environmental effects, host influences and a limited core microbiota by Hoffbeck, Carmen, Middleton, Danielle M R L, Nelson, Nicola J, Taylor, Michael W

“…An animal's gut microbiota plays an important role in host health, reproduction and digestion. However, many studies focus on only a few individuals or a…”
Get full text

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma by DANSON, S, LORIGAN, P, ARANCE, A, CLAMP, A, RANSON, M, HODGETTS, J, LOMAX, L, ASHCROFT, L, THATCHER, N, MIDDLETON, M. R

“…Temozolomide is an imidazotetrazine with a mechanism of action similar to dacarbazine and equivalent activity in melanoma. It is well tolerated and is a…”
Get full text